Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H43NO18 |
Molecular Weight | 645.6048 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 18 / 18 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H](O[C@@]2([H])O[C@H](C)[C@@H](N[C@@]3([H])C=C(CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O
InChI
InChIKey=CEMXHAPUFJOOSV-XGWNLRGSSA-N
InChI=1S/C25H43NO18/c1-7-13(26-9-2-8(3-27)14(33)18(37)15(9)34)17(36)20(39)24(41-7)44-23-12(6-30)42-25(21(40)19(23)38)43-22(11(32)5-29)16(35)10(31)4-28/h2,4,7,9-27,29-40H,3,5-6H2,1H3/t7-,9+,10+,11-,12-,13-,14-,15+,16-,17+,18+,19-,20-,21-,22-,23-,24-,25-/m1/s1
Molecular Formula | C25H43NO18 |
Molecular Weight | 645.6048 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 18 / 18 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:23:22 UTC 2023
by
admin
on
Fri Dec 15 16:23:22 UTC 2023
|
Record UNII |
T58MSI464G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2846
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
||
|
NDF-RT |
N0000000166
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
||
|
WHO-VATC |
QA10BF01
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
||
|
NCI_THESAURUS |
C29711
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
||
|
LIVERTOX |
NBK548181
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
||
|
WHO-ATC |
A10BF01
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
||
|
NDF-RT |
N0000175559
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
||
|
WHO-ATC |
A10BD17
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m1289
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | Merck Index | ||
|
84363
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
4527
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
DTXSID8046034
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
39
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
ACARBOSE
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
D020909
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
C983
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
T58MSI464G
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
1000521
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
56180-94-0
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
T-9
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
260-030-7
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
6791
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
Acarbose
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
SUB07368MIG
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
CHEMBL1566
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
DB00284
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
100000092276
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
9811704
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
56180-94-0
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
2376
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
16681
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | RxNorm | ||
|
T58MSI464G
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY | |||
|
758915
Created by
admin on Fri Dec 15 16:23:22 UTC 2023 , Edited by admin on Fri Dec 15 16:23:22 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Acarbose acts locally within the gastrointestinal tract, this low systemic bioavailability of parent compound.
IC50
|
||
|
TARGET->ACTIVATOR OF EXPRESSION |
Acarbose treatment stimulates postprandial GLP-1 secretion in patients with type 2 diabetes. Dependent on dose and saccharide or polysaccharide present. A single dose of 100 mg acarbose during an oral sucrose (disaccharide) load resulted in elevated GLP-1 levels compared to placebo (8, 10, 28, 29) whereas no effect was seen during oral glucose tolerance test (24), emphasizing that acarbose needs relevant carbohydrates to ‘act on’ in order to increase GLP-1 secretion. A single dose of 100 mg acarbose during an oral sucrose (disaccharide) load resulted in elevated GLP-1 levels compared to placebo (8, 10, 28, 29) whereas no effect was seen during oral glucose tolerance test (24), emphasizing that acarbose needs relevant carbohydrates to ‘act on’ in order to increase GLP-1 secretion.
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
Acarbose is exclusively metabolized within the gastrointestinal tract, principally by intestinal bacteria.
MAJOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
Other
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||